TSS
BDRX

Two Sigma Securities’s Biodexa Pharmaceuticals BDRX Stock Holding History

Two Sigma Securities’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26
Closed -$9.19K – 1752
2024
Q3 		$9.19K Buy
26
+10
+63% +$7.66K ﹤0.01% 2603
2024
Q2 		$18.4K Buy
+16
New +$21K ﹤0.01% 2714
2023
Q3 		– Hold
0
– -$2.6K – 2933
2023
Q2 		– Hold
0
– – – 2692
2022
Q3 		– Hold
0
– -$9K – 2601
2022
Q2 		– Hold
0
– – – 2065
2021
Q3 		– Hold
0
– -$47K – 1552
2021
Q2 		– Hold
0
– – – 1401
2019
Q2 		– Hold
0
– -$12K – 2078
2019
Q1 		– Hold
0
– – – 1714
2018
Q4 		– Hold
0
– – – 2064
2018
Q3 		– Hold
0
– – – 2505
2018
Q1 		– Hold
0
– -$9K – 2670
2017
Q4 		– Hold
0
– – – 1677

Other funds holding BDRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Two Sigma Securities's BDRX Position: Q4 2024 in Review

Two Sigma Securities sold out of Biodexa Pharmaceuticals (BDRX) in Q4 2024, closing a stake of 26 shares — an estimated $9.19K sold.

Two Sigma Securities first reported a position in BDRX in Q2 2024 and held it in 2 quarters. The position peaked at $18.4K in Q2 2024. 3 funds tracked by Wall St. Rank hold BDRX as of Q4 2024.

  • Two Sigma Securities reported no remaining Biodexa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Securities sold 26 Biodexa Pharmaceuticals shares in Q4 2024, an estimated $9.19K.
  • Two Sigma Securities first reported a position in Biodexa Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Two Sigma Securities's Biodexa Pharmaceuticals position peaked at $18.4K in Q2 2024.
  • 3 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q4 2024.

Based on Two Sigma Securities's 13F filing for Q4 2024, filed 14 Feb 2025.